Christopher T. Griffith

Christopher T. Griffith

Attorney Profile

Top Rated Intellectual Property Litigation Attorney in Chicago, IL

Green, Griffith & Borg-Breen LLP
 | 676 N. Michigan Avenue, Suite 3900
Chicago, IL 60611
Phone: 312-883-8008
Fax: 312-883-8001
Selected To Super Lawyers: 2016 - 2020
Licensed Since: 1988
Practice Areas:
  • Intellectual Property Litigation (70%),
  • Intellectual Property (30%)
    Attorney Profile

    Chris enjoys science and the law, but his true passion is helping companies succeed. His clients know him as a trusted advisor as well as an active facilitator who collaborates with client teams, developing effective IP strategies that get products to market on time and on budget.

    A founding partner of Green Griffith & Borg-Breen, Chris has more than 30 years of experience representing clients in the pharmaceutical, chemical, medical device and biotech fields. He has served as lead counsel in cases before both U.S. District Courts and the Court of Appeals for the Federal Circuit. Inter Partes reviews (IPRs) and post-grant proceedings under the AIA, as well as arbitrations and mediations, are also part of his practice.

    Chris was inspired to practice IP law while still in high school after a conversation with a family friend who was a pharmaceutical company patent attorney. His longtime focus on the field has given him a holistic, big-picture understanding of what clients need to reach their business objectives.

    While Chris advises clients on IP issues affecting various technologies, he has particular expertise regarding Orange Book and related FDA issues -- including those arising under the Hatch-Waxman Act, as well as issues affecting biologics and biosimilars under the BPCIA.

    His deep IP knowledge also supports a decades-long practice in developing and executing IP strategies – including patent application preparation and prosecution, portfolio development and management, opinions (freedom-to-operate and validity) and general guidance on new product development. Chris also has extensive experience in due diligence projects, providing guidance to companies, venture capital and other investment groups seeking information relevant to valuation and risk assessment. This experience extends to related trademark, trade dress and copyright matters.

    Chris enjoys teaching and has served as an adjunct professor at The John Marshall Law School, where he developed and taught a master’s-level patent law course. Chris also is active in pro bono matters, including volunteering for the Chicago Lawyers’ Committee for Civil Rights and the Northern District of Illinois Trial Bar Pro Bono Program.

    Before co-founding Green Griffith in 2015, Chris served as Leydig, Voit and Mayer Ltd.’s corporate secretary and as a member of the firm’s board of directors.

    About Christopher Griffith

    Admitted: 1988, Illinois

    Professional Webpage: http://greengriffith.com/christopher-t-griffith/

    Honors/Awards:

    • Selected as a “Life Sciences Star,” LMG Life Sciences
    • Named as a “Global IP Star,” Managing IP
    • Listed in Intellectual Asset Management's (IAM) Patent 1000 in Litigation
    • Selected by peers as a “Leading Lawyer” in Intellectual Property Law – Leading Lawyers Network
    • Recognized by Illinois Super Lawyers in Intellectual Property Litigation
    • Listed among the “Top Lawyers in Illinois” in Intellectual Property Law – Chicago Lawyer

    Special Licenses/Certifications:

    • U.S. Court of Appeals for the Federal Circuit; U.S. District Court for the Northern District of Illinois (Member, Trial Bar); U.S. District Court for the District of Arizona; U.S. District Court for the District of Columbia; U.S. District Court for the District of Delaware; U.S. District Court for the Southern District of Florida; U.S. District Court for the Northern District of Georgia;  U.S. District Court for the District of Nevada; U.S. District Court for the District of New Jersey; U.S. District Court for the Southern District of New York; U.S. District Court for the Northern District of Ohio; U.S. District Court for the Eastern District of Pennsylvania; U.S. District Court for the Western District of Washington; Registered Patent Attorney, U.S. Patent and Trademark Office, No. 33,392 (list includes pro hac vice admissions)

    Bar/Professional Activity:

    • Adjunct Professor, John Marshall Law School, Chicago, IL (Masters Level Course in Patent Law), 2002-2016

    Pro bono/Community Service:

    • Pro bono representation of prisoner in federal court seeking remedy for alleged improper healthcare.

    Scholarly Lectures/Writings:

    • “Biosimilars in US, EU and China: Where Are We Now and Where Are We Going?” 4th China Pharma IP Summit 2019, Shanghai, China, October 2019; “Section 101: Analysis of Recent Developments and Proposed Legislation,” International IP Skills Summit (IIPSS), Hyderabad, India, August 2019; “Patent Fundamentals Bootcamp 2019: An Introduction to Patent Drafting, Prosecution, and Litigation,” Moderator and Faculty Member, Practising Law Institute, Chicago, IL, May 2019; “Recent US Legal Developments Affecting Pharma-Related Contentious Matters,” 8th Annual Pharma IPR Conference, Mumbai, India, March 2019; “Navigating the IP Waters – Portfolio Development, FDA Exclusivities and Current Legal Issues Affecting the Journey Toward Commercialization of Biopharmaceutical Products in the US,” Asia Pharma R&D Leaders, Beijing, China, January 2019; “US Patent Litigation Trends: Past, Present and Future,” IIPLA 5th Dubai IP Congress, Dubai, UAE, January 2019;  “IP in the Courts: The Latest in IP Litigation,” World Intellectual Property Forum 2018 (WIPF), New Delhi, India, November 2018; “Navigating the IP/FDA Exclusivity Waters – Recent Developments Affecting the Journey to 505(b)(1), 505(b)(2), ANDA and Biologics Approval in the US,” 3rd Annual China Pharma IP Summit, Beijing, China, October 2018;  "Paragraph IV Litigation Trends, Analysis and Future Predictions" and "Strategic Considerations Concerning Inter Partes Reviews (IPRs) - Appearing in Dual Proceedings Before the U.S. District Court and PTAB," 3rd International IP Skills Summit (IIPSS), Hyderabad, India, June 2018;  “Interplay Between FDA Exclusivity, PTAB/IPRs and Hatch-Waxman Litigation on the Filing and Approval of 505(b)(2) and ANDA Applications,” 8th Annual Generic International Summit Asia, Shanghai, China, April 2018; “Latest Developments: Federal Courts and PTAB,” 7th Annual Pharma IPR Conference, Mumbai, India, March, 2018; “505(b)(2) NDAs v. ANDAs: Case Studies and Implications for Patent Portfolio Development and US Litigation,” 2nd China Pharma IP Summit 2017, Shanghai, China, December 2017; “Exploring New Developments in the Law of Divided and Inducement Infringement and Its Continuing Impact on Paragraph IV Litigation,” Paragraph IV Disputes Master Symposium, Chicago, IL, October 2017; “Selected U.S. Patent Law Topics Relevant to Pharmaceutical and Biotech Practice (Patentability, Validity and Infringement),” Advanced Training Seminars for the All-China Patent Agents Association, Chicago, IL, September 2014, July and November 2013; "Current Issues and Strategies in U.S. Patent Prosecution,” Advanced Training Seminar for Patent Reexaminers of the People’s Republic of China (SIPO), Chicago, IL, June and October 2013; “Selected U.S. Patent Law Topics Relevant to Pharmaceutical and Biotech Practice (Patentability, Validity and Infringement),” Advanced Training Seminars for the All-China Patent Agents Association and State Intellectual Property Organization (SIPO), Chicago, IL, May, September and October 2012; “Patent Litigation Issues in the Context of Biotechnology and Pharmaceutical Patents,” Advanced Training Seminar for the All-China Patent Agents Association, Chicago, IL, June and September 2011; U.S. Patent Law and Pharmaceuticals--Current and Future Trends, February, 2008 (Mumbai, India); October 2007: Current Issues and Strategies in U.S. Patent Prosecution: Advanced Training Seminar for Patent Reexaminers of the People's Republic of China (Chicago, Illinois); February 2007:  Recent Developments in U.S. Patent Law Affecting the Pharmaceutical Industry, Global Generic Pharmaceutical Conference 2007 (Mumbai, India); December 2006: Patent Considerations in the Pharmaceutical Industry, 58th Indian Pharmaceutical Congress (Mumbai, India); October 2006: Current Issues and Strategies in U.S. Patent Prosecution: Advanced Training Seminar for Patent Reexaminers of the People's Republic of China (Chicago, Illinois); June 2006:  Patent Barriers to Generic Pharmaceutical Entry, AIPLA Road Shows (Boston, Houston, San Jose); March 2006: The Changing Landscape of U.S. Patent Law, Global Generic Pharmaceutical Conference 2006 (Mumbai, India); October 2005:  Patent Issues and Trends In Cosmetic Formulations, Society of Cosmetic Chemists (Chicago); March 2003 & 2004:  Due Diligence in IP Business Transactions, Practicing Law Institute (Chicago) September, 2002; "Senate Passes Bill Revising Hatch-Waxman Framework for Generic Drug Approval," Regulatory Affairs FOCUS (Regulatory Affairs Professionals Society) March 2001;  Presentation on Process Patents, National Association of Pharmaceutical and Manufacturers Bulk Drug Workshop (New York City) January 2000;  Presentation on Process Patents and Related Issues, National Association of Pharmaceutical Manufacturers Annual Meeting (San Juan, Puerto Rico) 1999; Presentations on patent law (patentability/freedom-to-operate/opinions) to client R&D teams

    Educational Background:

    • B.S., Chemical and Biomedical Engineering, Michigan State University
    • JD, University of Houston
    • Masters Level Coursework in Biotechnology, Johns Hopkins University

    Industry Groups

    • Pharma; BioPharma; Biologics; Chemicals; Medical Devices
    Show More
    Office Location for Christopher T. Griffith

    676 N. Michigan Avenue
    Suite 3900
    Chicago, IL 60611

    Christopher T. Griffith:

    Last Updated: 6/10/2020

    Page Generated: 0.29927086830139 sec